Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | $14.7B | $14.3B | $14.7B | $15.4B | $16.3B | $17.9B | $11.9B | $11.5B | $11.4B | $11.9B | $11.1B | $9.4B | $7.7B | $6.9B | $6.8B | $6.1B | $5.5B | $5.1B | $5.1B | $2.9B | $1.6B |
| Bénéfice brut | $5.1B | $5.0B | $5.6B | $6.4B | $6.5B | $5.6B | $3.8B | $3.9B | $4.0B | $4.8B | $4.7B | $4.2B | $3.5B | $3.0B | $2.9B | $2.6B | $2.2B | $2.1B | $2.1B | $1.2B | $844M |
| Marge brute % | 34.8% | 35.1% | 38.1% | 41.7% | 40.0% | 31.2% | 31.8% | 33.9% | 35.0% | 40.2% | 42.4% | 44.7% | 45.7% | 44.0% | 42.8% | 41.8% | 40.7% | 40.7% | 40.3% | 40.1% | 52.3% |
| Résultat opérationnel (EBIT) | — | ($2.7B) | $10M | $766M | $1.6B | ($34M) | ($211M) | $716M | $906M | $1.4B | $699M | $1.5B | $1.4B | $1.1B | $1.1B | $1.0B | $722M | $523M | $298M | $372M | $428M |
| Marge opérationnelle % | — | -18.6% | 0.1% | 5.0% | 9.9% | -0.2% | -1.8% | 6.2% | 7.9% | 12.1% | 6.3% | 15.5% | 17.5% | 16.4% | 16.3% | 16.4% | 13.2% | 10.3% | 5.8% | 12.8% | 26.5% |
| Résultat net | ($411M) | ($3.5B) | ($634M) | $55M | $2.1B | ($1.3B) | ($670M) | $17M | $352M | $696M | $480M | $848M | $929M | $624M | $641M | $537M | $345M | $233M | ($196M) | ($1.5B) | $217M |
| Marge nette % | -2.8% | -24.6% | -4.3% | 0.4% | 12.8% | -7.1% | -5.6% | 0.1% | 3.1% | 5.8% | 4.3% | 9.0% | 12.0% | 9.0% | 9.4% | 8.8% | 6.3% | 4.6% | -3.8% | -52.2% | 13.5% |
| EBITDA | — | ($395M) | $2.8B | $3.5B | $6.4B | $4.5B | $2.0B | $2.7B | $3.0B | $3.2B | $2.1B | $2.3B | $1.9B | $1.6B | $1.7B | $1.5B | $1.1B | $947M | $735M | ($992M) | $683M |
| Bénéfice par action (EPS) | $-0.36 | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.68 | $1.30 | $0.92 | $1.70 | $2.34 | $1.58 | $1.52 | $1.22 | $1.05 | $0.76 | $-0.64 | $-5.90 | $0.99 |
| Actions en circulation (M) | — | 1,171M | 1,193M | 1,207M | 1,217M | 1,209M | 601M | 516M | 516M | 537M | 520M | 497M | 398M | 394M | 420M | 439M | 329M | 307M | 304M | 257M | 219M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de VTRS. /companies/us/VTRS
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms